|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
135,531,000 |
Market
Cap: |
332.05(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.47 - $3.22 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Xeris Biopharma Holdings is a pharmaceutical company. Co.'s primary focus is on therapies for patient populations in endocrinology, neurology, and gastroenterology. Co.'s products include: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages two years and older; Keveyis, the U.S. Food and Drug Administration approved therapy for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev (levoketoconazole), a cortisol synthesis inhibitor used for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Johnson Kenneth Erland |
See Remarks |
|
2019-07-01 |
4 |
A |
$9.72 |
$1,691 |
D/D |
174 |
3,419 |
|
- |
|
Prestrelski Steven |
Chief Scientific Officer |
|
2019-04-11 |
4 |
AS |
$9.56 |
$95,649 |
D/D |
(10,000) |
477,024 |
|
- |
|
Edick Paul R |
See Remarks |
|
2019-03-11 |
4 |
B |
$9.12 |
$273,585 |
D/D |
30,000 |
155,000 |
2.81 |
- |
|
Green Jeremy |
10% Owner |
|
2019-02-19 |
4 |
B |
$10.00 |
$5,880,000 |
I/I |
588,000 |
3,000,642 |
1.5 |
- |
|
Hecht Beth |
See Remarks |
|
2019-02-19 |
4 |
B |
$10.00 |
$25,000 |
D/D |
2,500 |
2,500 |
2.74 |
- |
|
Deutsch Barry M. |
See Remarks |
|
2019-02-19 |
4 |
B |
$10.00 |
$50,000 |
D/D |
5,000 |
28,292 |
2.74 |
- |
|
Johnson Kenneth Erland |
See Remarks |
|
2019-02-19 |
4 |
B |
$10.00 |
$10,000 |
D/D |
1,000 |
3,245 |
2.74 |
- |
|
Deerfield Private Design Fund Iii, L.p. |
Possible Member of 10% Group |
|
2019-02-11 |
4 |
S |
$15.00 |
$20,265 |
I/I |
(1,351) |
856,470 |
|
- |
|
Deerfield Private Design Fund Iii, L.p. |
Possible Member of 10% Group |
|
2019-02-08 |
4 |
S |
$15.11 |
$88,986 |
I/I |
(5,890) |
857,821 |
|
- |
|
Deerfield Private Design Fund Iii, L.p. |
Possible Member of 10% Group |
|
2019-02-07 |
4 |
S |
$15.00 |
$141,135 |
I/I |
(9,409) |
863,711 |
|
- |
|
Deerfield Private Design Fund Iii, L.p. |
Possible Member of 10% Group |
|
2019-02-06 |
4 |
S |
$15.00 |
$6,000 |
I/I |
(400) |
873,120 |
|
- |
|
Deerfield Private Design Fund Iii, L.p. |
Possible Member of 10% Group |
|
2019-02-05 |
4 |
S |
$15.07 |
$75,308 |
I/I |
(4,998) |
873,520 |
|
- |
|
Edick Paul R |
See Remarks |
|
2019-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
125,000 |
|
- |
|
Deerfield Private Design Fund Iii, L.p. |
Possible Member of 10% Group |
|
2019-01-29 |
4 |
S |
$15.14 |
$94,028 |
I/I |
(6,210) |
878,518 |
|
- |
|
Deerfield Private Design Fund Iii, L.p. |
Possible Member of 10% Group |
|
2019-01-28 |
4 |
S |
$15.00 |
$12,420 |
I/I |
(828) |
884,728 |
|
- |
|
Deerfield Private Design Fund Iii, L.p. |
Possible Member of 10% Group |
|
2019-01-25 |
4 |
S |
$15.08 |
$1,158,254 |
I/I |
(76,820) |
885,556 |
|
- |
|
Deerfield Private Design Fund Iii, L.p. |
Possible Member of 10% Group |
|
2019-01-24 |
4 |
S |
$15.03 |
$81,563 |
I/I |
(5,425) |
962,376 |
|
- |
|
Deerfield Private Design Fund Iii, L.p. |
Possible Member of 10% Group |
|
2019-01-23 |
4 |
S |
$16.35 |
$526,376 |
I/I |
(32,199) |
967,801 |
|
- |
|
Prestrelski Steven |
Chief Scientific Officer |
|
2019-01-14 |
4 |
AS |
$17.20 |
$132,459 |
D/D |
(7,700) |
469,324 |
|
- |
|
Prestrelski Steven |
Chief Scientific Officer |
|
2019-01-11 |
4 |
AS |
$0.00 |
$0 |
D/D |
(2,300) |
487,024 |
|
- |
|
Prestrelski Steven |
Chief Scientific Officer |
|
2018-12-26 |
4 |
S |
$15.82 |
$248,738 |
D/D |
(15,720) |
489,324 |
|
- |
|
Prestrelski Steven |
Chief Scientific Officer |
|
2018-12-24 |
4 |
OE |
$1.19 |
$18,707 |
D/D |
15,720 |
505,044 |
|
- |
|
Deerfield Private Design Fund Iii, L.p. |
Possible Member of 10% Group |
|
2018-06-25 |
4 |
B |
$15.00 |
$11,250,000 |
I/I |
750,000 |
1,498,666 |
1.5 |
- |
|
Deerfield Private Design Fund Iii, L.p. |
Possible Member of 10% Group |
|
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
1,748,666 |
874,333 |
|
- |
|
Green Jeremy |
|
|
2018-06-25 |
4 |
B |
$15.00 |
$10,000,020 |
I/I |
666,668 |
2,412,642 |
0.01 |
- |
|
83 Records found
|
|
Page 3 of 4 |
|
|